Breast Cancer Research and Treatment **30**: 315, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 30

Anderson TJ 153
Artagaveytia N 275
Azuine MA 233

Bajetta E 127
Balar DB 293
Baratta FS 243
Battersby S 153
Bhatavdekar JM 293
Bhatia P 263
Bhide SV 233
Bier B 213
Blankenstein MA 139
Bobin JY 275
Böcker W 213
Brekelmans CTM 223
Brodie AMH 1
Brueggemeier RW 31
Bulun SE 19
Buzzoni R 127

Campora E 133
Celio L 127
Ceriani RL 243
Cerrotta AM 127
Chan CM 243
Chin T 263
Clark GM 117
Cocconi G 57
Cohen AD 197
Cohen Y 197
Collette HJA 223
Cook LS 201
Coombes RC 81
Cornelisse CJ 139

De Coster R 89
Demers LM 95
Deurenberg JJM 223
Diamandis EP 179
Dockhorn-Dworniczak B 213
Douglas-Jones A 213
Dowsett M 81
Dukes M 103
Dyrhoff M 103

Ebeling K 283
Eliyahu D 167
Eliyahu S 167
Elliott RL 299,305
Erlichman C 205
Evans S 167

Faber JAJ 223
Fabian CJ 263
Falette N 275
Ferrari L 127
Feyzi JM 311
Fine S 205
Foekens JA 139

Gadalla T 205
Galante E 127
Gardin G 133
Garin E 275
Ghosh N 293
Giudici S 133
Gopas J 197

Hassanein RS 263
Head JF 299,305

Jasani B 213
Jewell WR 263
Johnson N 263
Jordan VC 159

Kaizer L 205
Kamel S 263
Karelia NH 293
Kimler BF 263
Koymans LMH 43

Lanfranco C 133
Lehiri M 233
Levesque MA 179
Lin F 263
Lippman M 167
Lönn S 147
Lönn U 147
Love RR 311

Mamby CC 311
Marrinetti A 127
McCoy JL 299,305
McKittrick R 263
Merlini L 133
Miglietta L 133
Miller EM 159
Miller WR 153
Misdorp W 139
Moereels H 43
Moore WP 263
Mühlemann K 201
Mulcahy RT 159

Naso C 133
Nilsson B 147
Nischan P 283
Noberasco C 127

Orifice S 127
Ozzello L 243

Paik S 167
Parker CJ 159
Patel DD 293
Peeters PHM 223
Plourde PV 103
Portengen H 139

Reed MJ 7
Repetto L 133
Rosen N 167
Rosso R 133
Rostan MC 275
Rutteman GR 139

Saez S 275
Santen RJ 1
Sarkaria JN 159
Schmid W 213
Schönborn I 283
Shah NG 293
Shoenfeld Y 197
Silverswärd C 147
Simon C 263
Simpson ER 19
Snoek E 89
Stenkvist B 147
Sutherland DJA 179

Telang NT 233
Teske E 139
Testore F 133
Tötsch M 213
Tranin AS 263
Trivedi SN 293

Vanden Bossche H 43
Venturino A 133
Vergara G 263
Vora HH 293
Vos JH 139

Warr D 205
Weiss NS 201
Wouters W 89

Yu H 179

Zalles C 263
Zeiger S 263
Zilembo N 127
Zwiebel J 167

Breast Cancer Research and Treatment **30**: 315, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Author index, Volume 30

Anderson TJ 153
Artagaveytia N 275
Azuine MA 233

Bajetta E 127
Balar DB 293
Baratta FS 243
Battersby S 153
Bhatavdekar JM 293
Bhatia P 263
Bhide SV 233
Bier B 213
Blankenstein MA 139
Bobin JY 275
Böcker W 213
Brekelmans CTM 223
Brodie AMH 1
Brueggemeier RW 31
Bulun SE 19
Buzzoni R 127

Campora E 133
Celio L 127
Ceriani RL 243
Cerrotta AM 127
Chan CM 243
Chin T 263
Clark GM 117
Cocconi G 57
Cohen AD 197
Cohen Y 197
Collette HJA 223
Cook LS 201
Coombes RC 81
Cornelisse CJ 139

De Coster R 89
Demers LM 95
Deurenberg JJM 223
Diamandis EP 179
Dockhorn-Dworniczak B 213
Douglas-Jones A 213
Dowsett M 81
Dukes M 103
Dyrhoff M 103

Ebeling K 283
Eliyahu D 167
Eliyahu S 167
Elliott RL 299,305
Erlichman C 205
Evans S 167

Faber JAJ 223
Fabian CJ 263
Falette N 275
Ferrari L 127
Feyzi JM 311
Fine S 205
Foekens JA 139

Gadalla T 205
Galante E 127
Gardin G 133
Garin E 275
Ghosh N 293
Giudici S 133
Gopas J 197

Hassanein RS 263
Head JF 299,305

Jasani B 213
Jewell WR 263
Johnson N 263
Jordan VC 159

Kaizer L 205
Kamel S 263
Karelia NH 293
Kimler BF 263
Koymans LMH 43

Lanfranco C 133
Lehiri M 233
Levesque MA 179
Lin F 263
Lippman M 167
Lönn S 147
Lönn U 147
Love RR 311

Mamby CC 311
Marrinetti A 127
McCoy JL 299,305
McKittrick R 263
Merlini L 133
Miglietta L 133
Miller EM 159
Miller WR 153
Misdorp W 139
Moereels H 43
Moore WP 263
Mühlemann K 201
Mulcahy RT 159

Naso C 133
Nilsson B 147
Nischan P 283
Noberasco C 127

Orifice S 127
Ozzello L 243

Paik S 167
Parker CJ 159
Patel DD 293
Peeters PHM 223
Plourde PV 103
Portengen H 139

Reed MJ 7
Repetto L 133
Rosen N 167
Rosso R 133
Rostan MC 275
Rutteman GR 139

Saez S 275
Santen RJ 1
Sarkaria JN 159
Schmid W 213
Schönborn I 283
Shah NG 293
Shoenfeld Y 197
Silverswärd C 147
Simon C 263
Simpson ER 19
Snoek E 89
Stenkvist B 147
Sutherland DJA 179

Telang NT 233
Teske E 139
Testore F 133
Tötsch M 213
Tranin AS 263
Trivedi SN 293

Vanden Bossche H 43
Venturino A 133
Vergara G 263
Vora HH 293
Vos JH 139

Warr D 205
Weiss NS 201
Wouters W 89

Yu H 179

Zalles C 263
Zeiger S 263
Zilembo N 127
Zwiebel J 167

Breast Cancer Research and Treatment **30**: 317-320, 1994.
© 1994 *Kluwer Academic Publishers. Printed in the Netherlands.*

Subject index, Volume 30

adipose tissue
  aromatase and extraglandular production of estrogens 19-29
aminoglutethimide
  as a first-generation aromatase inhibitor 57-80
  dosage and side effects 57-80
  mechanism 43-55
androstenedione
  postmenopausal source of estrogens 7-17
aneuploidy
  in aspirated cells of high vs. low risk women 263-273
Arimidex®
  as a fourth-generation aromatase inhibitor 103-111
aromatase
  gene regulation 19-29
  highest in breast quadrant with tumor, and in adipose stromal cells vs. adipocytes 19-29
  role in breast tumors 7-17
aromatase inhibitors
  4-hydroxyandrostenedione and increased serum IGF-I 127-132
  non-steroidal — mechanisms 43-55
  overview 1-6
  special issue 1-111
  steroidal — mechanisms 31-42

benign breast disease
  a risk factor for "interval cancer" in screening study 223-232
  no metallothionein overexpression 213-221
betel leaf extract
  in chemoprevention of animal mammary tumor models 233-242
biomarkers
  aneuploidy, ER, and EGFR in breast aspirates of high vs. low risk women 263-273

CA 15-3
  more effective as serum marker than immunosuppressive acidic protein (IAP) 197-200
carcinoembryonic antigen (CEA)
  associations with p53, PSA, ER, and PgR 179-195
β-carotene
  in chemoprevention of animal mammary tumor models 233-242
catechin (a natural plant product)
  in chemoprevention of animal mammary tumor models 233-242
CGS 20267 and CGS 47465 (aromatase inhibitors)
  mechanism 43-55
chemoprevention
  by natural plant products in animal mammary tumor models 233-242
chemotherapy
  folinic acid and 5FU — phase II 205-209
  weekly mitoxantrone/5FU/leucovorin — phase II 133-137
coagulation
  no change in protein S or protein C caused by tamoxifen (24 months) 311-314
cyclic AMP binding proteins
  increased total and type I in proliferating vs. resting normal breast tissue 153-158
CYP19 (aromatase) gene
  alternative promoter use and local elevations 19-29

DMBA-induced rat mammary tumors
  chemoprevention by natural plant products 233-242
dog mammary tumors
  no correlation of EGFR with ER, PgR, or aggressiveness 139-146
ductal carcinoma *in situ* (DCIS)
  overexpression of metallothioneins 213-221

EGFR
  no correlation with ER, PgR, or aggressiveness in dog mammary tumors 139-146
endocrine therapy
  aromatase inhibitors — special issue 1-111

endocrine therapy *(cont.)*
4-hydroxyandrostenedione and increased serum IGF-I 127-132
enzyme-activated inhibitors
steroidal aromatase inhibitors 31-42
epidemiology
risk factor study for "interval cancers" 223-232
epidermal growth factor (EGF)
in serum, vs. prolactin as a prognostic factor 293-297
epidermal growth factor receptor (EGFR)
in aspirated cells of high vs. low risk women 263-273
mRNA by PCR, vs. ligand binding assay 275-282
erbB-2
PCR assay of amplification in paraffin-embedded tissue, and prognosis 147-152
estrogen receptor (ER)
associations with p53, CEA, PSA 179-195
in aspirated cells of high vs. low risk women 263-273
in dog mammary tumors — no correlation with EGFR 139-146
no correlation with lymphocyte immunity to tumor antigens 299-304
no correlation with EGFR mRNA (PCR assay) 275-282
estrogens
role of locally formed estrone in breast tumors 7-17

fadrozole (CGS 16949A)
as a new non-steroidal aromatase inhibitor — phase I 95-102
mechanism 43-55
ferritin
no correlation with lymphocyte immunity to tumor antigens 305-309
fine needle aspirates
aneuploidy, ER, and EGFR in breast aspirates of high vs. low risk women 263-273
5-fluorouracil (5FU)
and folinic acid — phase II 205-209
weekly with mitoxantrone, leucovorin — phase II 133-137
folinic acid
and 5FU — phase II 205-209

gene amplification
PCR assay of amplification in paraffin-embedded tissue, and prognosis 147-152

height and weight
as risk factors for "interval cancer" in screening study 223-232
hepatocellular carcinoma
no clear increase in U.S. with introduction of tamoxifen 201-204
HER-2/neu oncogene
PCR assay of amplification in paraffin-embedded tissue, and prognosis 147-152
4-hydroxyandrostenedione
and increased serum IGF-I 127-132
as a second-generation aromatase inhibitor 81-87
hyperplastic breast lesions
no metallothionein overexpression 213-221

immunohistochemistry
metallothioneins in normal and malignant breast tissue 213-221
immunology
lymphocyte immunity to tumor antigens — no correlation with ER, PgR, iron-binding proteins 299-309
immunosuppressive acidic protein (IAP)
ineffective as serum marker, cf. CA 15-3 197-200
insulin-like growth factor I (IGF-I)
explaining tallness as a risk factor for "interval cancer"? 230
increased serum levels with 4-hydroxy-androstenedione 127-132
in serum, vs.prolactin as a prognostic factor 293-297
interval cancer
risk factors in screening study 223-232
iron-binding proteins
ferritin, transferrin — no correlation with lymphocyte immunity to tumor antigens 305-309

letrozole (CGS 20267)
as a new non-steroidal aromatase inhibitor — phase I 95-102
mechanism 43-55

leucovorin
weekly with mitoxantrone, 5FU — phase II 133-137
lymphocytes
immunity to tumor antigens — no correlation with ER, PgR, iron-binding proteins 299-309

mammography
characteristics of "missed" breast cancers 223-232
MCF-7 cells
no change of radiation sensitivity by 4-hydroxytamoxifen 159-165
mechanism-based inhibition
steroidal aromatase inhibitors 31-42
menopause, artificial
a risk factor for "interval cancer" in screening study 223-232
metallothioneins
overexpression in ductal carcinomas 213-221
mitoxantrone
weekly with 5FU, leucovorin — phase II 133-137
monoclonal antibodies
BrE-3 anti-mucin in prognosis 243-261
mouse mammary tumor model (MMTV)
chemoprevention by natural plant products 233-242
mucins
BrE-3 MAb epitope and prognosis 243-261

natural history of breast cancers
different risk factors for interval vs. screen-detected cancers 223-232

oral contraceptives
and improved prognosis 283-292

p53 tumor suppressor
associations with CEA, PSA, ER, and PgR 179-195
introduction of wild-type or temperature-sensitive mutant p53 genes suppresses breast cancer cell growth 167-177
polymerase chain reaction (PCR)
competitive RT-PCR for aromatase transcripts 19-29
EGFR mRNA, vs. ligand binding assay 275-282
method to assay gene amplification in paraffin-embedded tissue 147-152
progesterone receptor (PgR)
associations with p53, CEA, PSA 179-195
in dog mammary tumors — no correlation with EGFR 139-146
increased sensitivity of immunohistochemistry vs. ligand binding assay 299-304
no correlation with lymphocyte immunity to tumor antigens 299-304
prognostic factors
associations among p53, CEA, prostate-specific antigen (PSA), ER, and PgR 179-195
BrE-3 anti-mucin MAb epitope in paraffin sections 243-261
lymphocyte immunity to tumor antigens — no correlation with ER, PgR, iron-binding proteins 299-309
oral contraceptive use and improved survival 283-292
serum prolactin (preliminary study) 293-297
prolactin, serum
as a prognostic factor 293-297
proliferation
increased total and type I cyclic AMP binding proteins, vs. resting breast 153-158
introduction of wild-type p53 genes suppresses breast cancer cell growth 167-177
prostate-specific antigen (PSA)
associations with p53, CEA, ER, and PgR 179-195

radiation sensitivity
no change by 4-hydroxytamoxifen in MCF-7 cells 159-165
risk factors
aneuploidy, ER, and EGFR in breast aspirates of high vs. low risk women 263-273
for "interval cancer" in screening study 223-232
rogletimide
mechanism 43-55

screening
risk factors for "interval cancer" (DOM project) 223-232

serum markers
immunosuppressive acidic protein ineffective, cf. CA 15-3 197-200

tamoxifen
and incidence of hepatocellular carcinoma — no clear increase in U.S. 201-204
no change of MCF-7 radiation sensitivity by 4-hydroxytamoxifen 159-165
tamoxifen toxicity
thrombophlebitis — no change in procoagulant protein S or protein C 311-314
testololactone
as a first-generation aromatase inhibitor 57-80
transferrin
no correlation with lymphocyte immunity to tumor antigens 305-309
tumeric
in chemoprevention of animal mammary tumor models 233-242
tumor antigens
lymphocyte immunity — no correlation with ER, PgR, iron-binding proteins 299-309
tumor markers
serum immunosuppressive acidic protein ineffective, cf. CA 15-3 197-200
tumor suppressors
introduction of wild-type p53 genes suppresses breast cancer cell growth 167-177

vorazole
as a new non-steroidal aromatase inhibitor 89-94
mechanism 43-55
pharmacology and pharmacokinetics 89-94

ZD1033
see Arimidex®